Open an account

Generate Biomedicines

GENB · NASDAQ

$12.90+$0.34 (+2.71%)TodayMarket closed ·
Prev close $12.56

About GENB

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company is headquartered in Somerville, Massachusetts and currently employs 312 full-time employees. The company went IPO on 2026-02-27. The firm is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Employees
312
Headquarters
Somerville, Massachusetts
Listed
Feb 27, 2026
Sector
Health Care
Industry
Biotechnology
Website
generatebiomedicines.com

GENB key statistics

Market cap
1.66B
Price-earnings ratio
—
Dividend yield
—
Average volume
1.04M
Volume
523.36K
Open price
$12.53
High today
$13.07
Low today
$12.44
52 Week high
$22.67
52 Week low
$11.00

Generate Biomedicines (GENB) at a glance

As of Oct 20, 2026, Generate Biomedicines (GENB) shares are priced at $12.90, giving the company a market cap of 1.66B.

Today the stock has traded between $12.44 and $13.07. The current price is 3.7% above the day's low and 1.3% below its high.

Volume so far is 523.36K shares, below the average of 1.04M shares a day.

Over the past year Generate Biomedicines has ranged from $11.00 to $22.67, and now sits 16% of the way up that range.

Generate Biomedicines met or beat analyst EPS estimates in 0 of the last 2 quarters. In Q2 FY26 it reported -$0.52 per share against an estimate of -$0.5059.

The average analyst price target is $27.54, 113.5% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $27.54
Low
$22.22
Now
$12.90
High
$31.50

GENB earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 2 quarters.

  1. Q1 FY26: reported -$1.06 per share against an estimate of -$0.51
  2. Q2 FY26: reported -$0.52 per share against an estimate of -$0.5059

GENB news

  • Vandana Singh

    Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market

  • Press releaseGlobe Newswire

    AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

  • Press releaseGlobe Newswire

    Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

  • 'Zealand Pharma Makes Deal With Generate Worth Up to $1.2 Billion' - Bloomberg

  • Press releaseGlobe Newswire

    Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

  • Press releaseGlobe Newswire

    Generate Biomedicines Inc. to Participate in September Investor Conferences

  • Press releaseGlobe Newswire

    Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Avi Kapoor

    Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Similar companies

Companies in the same industry as Generate Biomedicines

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.